Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerging Company Profiles

Set Alert for Emerging Company Profiles

Step Pharma Aims To Become CTP Synthase 1 Leader, Starting With Aggressive Lymphoma

Emerging Company Profile: The French firm, which is developing the lead CTP synthase 1 inhibitor in the pipeline, plans to address a range of cancers with its highly selective approach.

Emerging Company Profile Companies

AdipoPharma Targets Root Cause Of Diabetes With First ‘Adipeutic’ Drug Candidate

Emerging Company Profile: The French biotech is developing a constrained peptide that targets an interaction in body fat tissue in the hopes of treating type 2 diabetes.

Emerging Company Profile Metabolic Disorders

PanTher Reimagines Cardiology Interventions As Precision Oncology Platform

Emerging company profile: The US biotech is wrapping up a Phase I trial for its lead pancreatic cancer program at the end of this year and hopes to expand its precision drug-device combination platform to a range of other solid tumors.

Emerging Company Profile Cancer

Ariceum Hopes To One-Up Novartis Drug With Potent Radiopharmaceutical Focus

Emerging Company Profile: The private German biotech Ariceum has just launched with a €25m financing to advance its lead radioligand candidate, satoreotide, into Phase I development and hopes its antagonist approach could give Novartis’s Lutathera a run for its money.

Emerging Company Profile Cancer

BiologicsMD Uses Unique Fusion Proteins To Treat Alopecia Safely

Emerging Company Profile: The US biotech is developing a series of recombinant fusion proteins to tackle alopecia and other diseases without supressing the immune system.

Emerging Company Profile Companies

Unicyte’s Unique Stem Cell Approach Could Cure Children With Rare Disorder

Emerging Company Profile: Swiss biotech Unicyte is using donor-derived liver stem cells across a range of therapeutic areas, with its lead asset showing curative potential in urea cycle disorders.

Emerging Company Profile Liver & Hepatic

Beckley Psytech Takes On Rare Disease With Psychedelics

Emerging Company Profile: The British biotech, co-founded by experimental researcher Lady Amanda Feilding, is developing psychedelics therapeutics for a rare but debilitating headache disorder and mental health disorders.

Emerging Company Profile Neurology

OncoResponse Mines PD-1 Therapy “Elite Responders” For IO Breakthroughs

Emerging Company Profile: Harvesting blood and tissue samples from patients treated with PD-1 immunotherapy, OncoResponse is developing antibodies it believes can transform cold solid tumors into hot.

Emerging Company Profile Business Strategies

Neuroplast Develops Safer Stem Cell Therapy For Spinal Injuries

Emerging Company Profile: The Dutch biotech is working on a more streamlined autologous stem cell therapy for traumatic spinal cord injury, an indication currently dominated by allogeneic treatments which present safety issues.

Emerging Company Profile Neurology

Rallybio Looks To Deals To Grow ‘Transformative’ Rare Disease Pipeline

Emerging Company Profile: Armed with the insight of its ex-Alexion leaders, Rallybio is eyeing a spate of deals to develop and commercialize transformative drugs for rare diseases.

Emerging Company Profile Rare Diseases

Cybin Uses Psychedelic Mushroom Derivative To Tackle Depression With Improved Safety

Emerging Company Profile: Cybin’s novel approach to psilocybin therapeutics aims for better safety, shorter duration and less variability through the process of deuteration.

Emerging Company Profile Neurology

BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals

Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.

Companies StartUps and SMEs
See All
UsernamePublicRestriction

Register